Tuberculosis, anti-TNF agents and other immunosuppressants: Evolution of preventitive strategies;Tuberculose, agents anti-TNF et autres immunosuppresseurs: Évolution des stratégies de prévention

Revue des Maladies Respiratoires

Volumn 25, Issue 10, 2008, Pages 1237-1249

  Liote H ^a  

^a HÔPITAL TENON   (France)

Author keywords

Anti TNF agents; Immunosuppressive drugs; Recommendations; Steroid therapy; Tuberculosis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALKYLATING AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; EVEROLIMUS; FLUDARABINE; GAMMA INTERFERON; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

COMORBIDITY; EPIDEMIOLOGICAL DATA; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCREENING TEST; SPAIN; STEROID THERAPY; TUBERCULOSIS; UNITED STATES;

EID: 58149359580     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0761-8425(08)75089-7     Document Type: Review

References (66)

1. Lioté H : Complication respiratoires des nouveaux traitements de la polyarthrite rhumatoïde. Rev Mal Respir 2004 ; 21 : 1107-15.
2. Hanekom W, Abel B, Scriba T : Immunological protection against tuberculosis. S Afr Med J 2007 ; 97 : 973-7.
3. Halloran P : Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004 ; 351 : 2715-29.
4. Kaplan MH, Armstrong D, Rosen P : Tuberculosis complicating neoplasic disease. A review of 201 cases. Cancer 1974 ; 33 : 850-8.
5. Yuen KY, Woo PCY : Tuberculosis in blood and marrow transplant recipients. Hematol Oncol 2002 ; 20 : 51-62.
6. Nair R, Prabhash K, Sengar M, Bakshi A, Gujral S, Gupta S, Parikh P : The effect of short-term intensive chemotherapy on reactivation of tuberculosis. Ann Oncol 2007 ; 18 : 1243-5.
7. Kim HA, Yoo CD, Beak HJ, Lee EB, Ahn C, Han JS, Kim S, Lee JS, Choe KW, Song YW : Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998 ; 16 : 9-13.
8. Yun JE, Lee SW, Kim TH, Jun JB, Jung S, Bae SC, Kim TY, Yoo DH : The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 2002 ; 20 : 127-32.
9. Vadillo F, Hernandez-Garcia C, Pato E : Incidencia y caracteristicas de la tuberculosis en pacientes con enfermedades reumaticas. Rev Clin Esp 2003 ; 203 : 178-82.
10. Sayarlioglu M, Inanc M, Kamali S, Cefle A, Karaman O, Gul A, Ocal L, Aral O, Konice M : Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus 2004 ; 13 : 274-8.
11. Mok MY, Lo Y, Chan TM, Wong WS, Lau CS : Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. J Rheumatol 2005 ; 32 : 609-15.
12. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Aguirre C : High risk of tuberculosis in systemic lupus erythematosus? Lupus 2006 ; 15 : 232-5.
13. Kobashi Y, Matsushima T : Clinical analysis of pulmonary tuberculosis in association with corticosteroid therapy. Internal Medicine 2002 ; 41 : 1103-10.
14. Tam LS, Li EK, Wong SM, Szeto CC : Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol 2002 ; 31 : 296-300.
15. Stuck AE, Minder CE, Frey FJ : Risk of infectious complications in patients taking glucocorticosteroïds. Rev Infect Dis 1989 ; 11 : 954-63.
16. European best practice guidelines for renal transplantation (Expert group) : Section IV: Long-term management of the transplant recipient. IV.7.2. Late infections: Tuberculosis. Nephrol Dial transplant 2002 ; 1 : 39-43.
17. Gilliland WR, Tsokos GC : Prophylactic use of antibiotics and immunisations in patients with SLE. Ann Rheum Dis 2002 ; 61 : 191-2.
18. Hernández-Cruz B, Ponce-de-León-Rosales S, Sifuentes-Osornio J, Ponce-de-León-Garduño A, Díaz-Jouanen E : Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. Clin Exp Rheumatol 1999 ; 17 : 81-7.
19. Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR : Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 2002 ; 61 : 251-3.
20. Hertig A, Rondeau E : Immunomodulation dans la greffe rénale : ce qui a changé en 20 ans. Réanimation 2006 ; 15 : 253-8.
21. Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, Blanes M, Rufí G, Moreno A, Gurguí M, Hayek M, Lumbreras C, Cantarell C : Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, Gesitra. Transplantation 1997 ; 63 : 1278-86.
22. Korner M, Hirata N, Tenderich G, Minami K, Mannebach H, Kleesiek K, Körfer R : Tuberculosis in heart transplant recipients. Chest 1997 ; 111 : 365-9.
23. Biz E, Pereira C, Moura L, Sesso R, Vaz ML, Silva Filho AP, Pestana JO : The use of cyclosporine modifies the clinical and histopathological presentation of tuberculosis after renal transplantation. Rev Inst Med trop Sao Paulo 2000 ; 42 : 225-30.
24. Park YS, Choi JY, Cho CH, Kang JK, Kim KS, Choi JS, Lee WJ, Kim BR, Song SY : Clinical outcomes of tuberculosis in renal transplant recipients. Yonsei Medical Journal 2004 ; 45 : 865-72.
25. Atasever A, Bacakoglu F, Toz H, Basoglu OK, Duman S, Basak K, Guzelant A, Sayiner A : Tuberculosis in renal transplant recipients on various immunosuppressive regimens. Nephrol Dial Transplant 2005 ; 20 : 797-802.
26. Hsu MS, Wang JL, KO WJ, Lee PH, Chou NK, Wang SS, Chu SH, Chang SC : Clinical features and outcome of tuberculosis in solid organ transplant recipients. Am J Med Sci 2007 ; 334 : 106-10.
27. Passalent L, Khan K, Richarson R, Wang J, Dedier H, Gardam M : Detecting latent tuberculosis infection in hemodialysis patients : A head-to-head comparison of the T-SPOT.TB test, Tuberculin Skin Test, and an Expert Physician Panel. Clin J Am Soc Nephrol 2007 ; 2 : 68-73.
28. Mercadal L, Foltz V, Isnard-Bagnis C, Ourahma S, Deray G : Tuberculosis after conversion from azathioprine to mycophenolate mofetil in a long-term renal transplant recipient. Transplant Proc 2005 ; 37 : 4241-3.
29. Tsai MK, Lee CY, Hu RH, Lee PH : Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients. J Formos Med Assoc 2007 ; 106 : 372-9.
30. Prokopenko E, Scherbakova E, Vatazin A, Pasov S, Budnikova N, Agafonova S : Does mycophenolate mofetil increase the incidence of infections in renal transplant recipients? Drugs Exp Clin Res 2005 ; 31 : 199-205.
31. Chen CH, Lian JD, Cheng CH, Wu MJ, Lee WC, Shu KH : Mycobacterium tuberculosis infection following renal transplantation in Taiwan. Transpl Infect Dis 2006 ; 8 : 148-56.
32. Ergun I, Ekmekci Y, Sengul S, Kutlay S, Dede F, Canbakan B, Erbay B : Mycobacterium tuberculosis infection in renal transplant recipients. Transplant Proc 2006 ; 38 : 1344-5.
33. Vikrant S, Agarwal SK, Gupta S, Bhowmik D, Tiwari SC, Dash SC, Guleria S, Mehta SN : Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis 2005 ; 7 : 99-108.
34. Naqvi R, Akhtar S, Noor H, Saeed T, Bhatti S, Sheikh R, Ahmed E, Akhtar F, Naqvi A, Rizvi A : Efficacy of isoniazid prophylaxis in renal allograft recipients. Transplantation proceedings 2006 ; 38 : 2057-8.
35. Gardam MA, Keystone EC : Anti-TNF agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 2003 ; 3 : 148-55.
36. Havlir DV, Barnes PF : Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999 340 : 367-73.
37. Bieber J, Kavanaugh A : Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol 2004 ; 22 : S126-33.
38. Wolfe F, Michaud K, Anderson J : Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004, 50 : 372-9.
39. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Biobadaser Group : Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003 ; 48 : 2122-7.
40. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N : Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005 ; 52 : 1986-92.
41. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC : Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007 ; 34 : 706-11.
42. Keane J, Gershon S, Wise RP : Tuberculosis associated with infliximab, a tumor necrotising factor neutralizing agent. N Engl J Med 2001 ; 345 : 1098-104.
43. Garcia-Vidal C, Rodriguez-Fernandez S, Martinez-Lacasa J, Salavert M, Vidal R, Rodríguez Carballeira M, Garau J : Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2006 ; 40 : 756-9.
44. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, Lagrange Ph, Sereni D, Autran B : Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2007 ; 21 : 882-4.
45. Keane J : TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005 ; 44 : 714-20.
46. Ehlers S : Why does TNF-targeted therapy reactivate tuberculosis? J Rheumatol 2005 ; 32 : S35-9.
47. Wallis RS : Reactivation of latent tuberculosis by TNF blockade: the role of interferon γ. J Investig Dermatol Symp Proc 2007 ; 12 : 16-21.
48. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, Chan J, Flynn JL : Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007 ; 195 : 1643-50.
49. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS : Tumor-necrosis-factor blockers : differential effects on mycobacterial immunity. J Infect Dis 2006 ; 194 : 486-92.
50. Reiling N, Schneider D, Ehlers S : Mycobacterium tuberculosis-induced cell death of primary human monocytes and macrophages is not significantly modulated by tumor necrosis factor-targeted biologicals. J Investig Dermatol Symp Proc 2007 ; 12 : 26-33.
51. Furst DE, Cush J, Kaufmann F, Siegel J, Kurth R : Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002 ; 61 : 62-3.
52. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M : Biobadaser Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005 ; 52 : 1766-72.
53. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 2005 ; 60 : 800-5.
54. Ledingham J, Deighton C ; British Society for Rheumatology : Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005 ; 44 : 157-63.
55. www.afssaps.santé.fr
56. Perez J, Kupper H, Radin A, Spencer-Green G : (Abbot Laboratories, Germany). Impact of screening for latent TB prior to initiating anti-TNF therapy. ACR 2005 ; abstract number 1877.
57. Gómez-Reino JJ, Carmona L, Angel Descalzo M ; Biobadaser Group : Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007 ; 57 : 756-61.
58. Raval A, Akhavan-Toyserkani G, Brinker A, Avigan M : Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007 ; 147 : 699-702.
59. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D : Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006 ; 10 : 1127-32.
60. Herrmann JL, Bergeron A : Screening for tuberculosis before TNF-α antagonist initiation : Are current methods good enough? Joint Bone Spine 2007 ; 75 : 194-7.
61. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D'Amico R, Marchegiano P, Rumpianesi F, Fabbri LM, Richeldi L : Routine hospital use of a new commercial whole blood interferon-γ assay for the diagnosis of tuberculosis infection. Am J Crit Care Med 2005 ; 172 : 631-5.
62. Piana F, Codecasa LR, Cavallerio P, Ferrarese M, Migliori GB, Barbarano L, Morra E, Cirillo DM : Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006 ; 28 : 31-4.
63. Sester U, Junker H, Hodapp T, Schütz A, Thiele B, Meyerhans A, Köhler H, Sester M : Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 2006 ; 21 : 3258-68.
64. Lawn SD, Bangani N, Vogt M, Bekker LG, Badri M, Ntobongwana M, Dockrell HM, Wilkinson RJ, Wood R : Utility of interferon-gamma ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa. BMC Infect Dis 2007 ; 7 : 99.
65. Dinser R, Fousse M, Sester U, Albrecht K, Singh M, Köhler H, Müller-Ladner U, Sester M : Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novelflow-cytometric interferon-gamma release assay. Rheumatology 2008 ; 47 : 212-8.
66. CDC. Guidelines for using the Quantiferon-TB gold test for detecting M. tuberculosis infection, United States. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. MMWR 2005 ; 54 (RR15) : 49-55.